| The History and Future of CAR T with Bruce Levine | Jorge Conde | Raising Health | 2024-08-06 | | Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, joins Jorge Conde, general partner, and Ginger Liau, partner at a16z Bio + Health. Bruce talks about how his time working in a lab at the Children’s Hospital of Philadelphia inspired him to work on translational therapies. Together, they also discuss barriers to access for cancer therapeutics and how the fight against cancer is progressing. Additional disclosures for Bruce include: Scientific Advisory Boards: Avectas, Capstan (Chair), Immuneel, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, ThermoFisher Pharma Services, UTC Therapeutics. Scientific Advisor: Kite. Past: Akron, Vycellix Co-Founder and equity holder: Tmunity Therapeutics (acquired by Kite), Capstan Therapeutics Board of Directors: Alliance for Cancer Gene Therapy Conflict of interest is managed in accordance with University of Pennsylvania policy and oversight. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. |
| Building the First CAR T Company | Jorge Conde | The a16z Show | 2020-02-07 | | with @OzAzamTmunity1, @JorgeCondeBio, and @omnivorousread CAR T therapy, the groundbreaking new medicines that uses engineered T-cells to attack cancer, has been so effective in childhood leukemias that we believe it may actually be a potential cure. But this isn't just one new medicine, it's an entirely new therapeutic tool—and a total paradigm shift from most traditional medicines we've seen before. Tmunity CEO Usman "Oz" Azam was previously the head of Cell and Gene Therapies at Novartis, in many ways the first CAR T company and the team brought us blood cancer CAR T-cell therapy Kymriah—the first cell-based gene therapy to be approved in the US. In this conversation, Azam discusses with a16z's general partner Jorge Conde and Hanne Tidnam what CAR T therapy really is and how it all works. The conversation begins with the “patient and cell journey” of this treatment and how this medicine is developed, manufactured, delivered to patients; why exactly it's so different traditional medicines; what it will take to make these new medicines work on more kinds of cancer, scale to more patients, and cost less; and finally, what company building lessons can be learned from building the first CAR T company of its kind from the ground up. This episode was recorded at the annual a16z Summit. |